# Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

> **NCT03715127** · PHASE2 · COMPLETED · sponsor: **University of Zurich** · enrollment: 55 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Psilocybine oral capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03715127
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2021-10-12
- **Final completion:** 2022-04-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2022-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715127, "Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03715127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*